MedTrace Logo

Factors Associated With Successful Completion of MRI in Children Undergoing a Vigil Sedation With Dexmedetomidin

NCT06203522 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 81

Last updated 2024-08-09

No results posted yet for this study

Summary

This is a retrospective cohort study aiming to determine whether the use of Dexmedetomidine (DEX) to sedate children prior to MRI scanning is more or less effective in children with autism spectrum disorders or other neurodevelopmental disorders compared to other children.

Conditions

  • Procedural Sedation
  • EEG
  • MRI

Interventions

PROCEDURE

Data collection of successful completion of MRI

age, sex, autistic disorders, epilepsy, polyhandicap, non-autistic neurodevelopmental disorders, success of MRI procedure

Sponsors & Collaborators

  • Centre Hospitalier Régional Metz-Thionville

    lead OTHER

Principal Investigators

  • Anne Charlotte CULLIER, MD · CHR Metz Thionville Hopital Mercy

Eligibility

Min Age
3 Months
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-01
Primary Completion
2024-03-30
Completion
2024-03-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06203522 on ClinicalTrials.gov